Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

BPC-157 vs GHK-Cu

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors GHK-Cu

GHK-Cu has the stronger footing, though it is thin: small human cosmetic studies of topical creams report improvements in aged and photodamaged skin, its one small randomized trial, of topical GHK-Cu after laser resurfacing, found no objective benefit, and topical GHK-Cu is sold lawfully as a cosmetic ingredient without a prescription. BPC-157 has no controlled human trial and rests on rodent tendon and gut studies, and it is not FDA approved or on the 503A bulks list; it is one of six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription, which is not binding and does not change its evidence grade. They target different problems: GHK-Cu is a skin and wound peptide, BPC-157 is promoted for tendon, ligament, and gut healing, and neither has human data for injection.

Verified: Verified Oct 28, 2026
BPC-157 oralSponsoredFrom Bodybuilding Peptides
Glow blend (GHK-Cu / BPC-157 / TB-500)SponsoredFrom Bodybuilding Peptides

Which is better, BPC-157 or GHK-Cu?

GHK-Cu is graded human RCT because one small randomized trial of topical GHK-Cu is indexed (13 patients completed it after laser resurfacing), but that trial found no difference in redness, wrinkles, or skin quality by blinded assessment, so the grade describes how the evidence was gathered, not whether GHK-Cu works. Small cosmetic studies cited through reviews report improved skin firmness, elasticity, and wrinkles, and topical products are lawful to buy. BPC-157 is graded animal only, with no controlled human trial; it is not on the 503A bulks list, and its only compounded path is HHS's draft enforcement discretion policy, which is not binding and may be revisited. The edge applies to topical skin use; for tendon or gut problems neither has human evidence, and the GHK-Cu human data are small studies summarized mostly by the peptide's discoverer. [2] [6] [7] [8] [10] [13] [15]

How do BPC-157 and GHK-Cu compare?

BPC-157 and GHK-Cu compared by dimension
DimensionBPC-157GHK-CuFavored
What it is [4] [7]Synthetic 15 amino acid fragment of a gastric protein (body protection compound).Naturally occurring tripeptide (glycyl-histidyl-lysine) bound to copper, found in human plasma, saliva, and urine.
Evidence grade [2] [6] [12] [13]Animal only. No controlled human trial; human data limited to three small uncontrolled pilot reports from one clinic.Human RCT for topical use: one small randomized trial after laser resurfacing (13 completers) found no objective benefit; other data are small cosmetic studies cited through reviews. No human trial of injected GHK-Cu.
Main use case in the literature [1] [4] [5] [6]Tendon, ligament, muscle, and gastrointestinal healing in rodents, including NSAID induced ulcers and fistulas.Skin aging and photodamage in humans (topical), plus wound, hair follicle, and bone healing in rodents, pigs, and dogs.
Proposed mechanism [3] [5] [7]Growth factor receptor upregulation, nitric oxide system modulation, and VEGFR2 driven angiogenesis in animal and cell models.Delivers copper to cells, attracts repair cells, increases collagen, elastin, and glycosaminoglycan synthesis, and dampens NF-kB and TNF-alpha signaling in cell and animal models.
Routes with data [4] [6]Injection, oral in drinking water, and topical in rodents. No human route has published data.Topical cream or serum in humans (the only form with human data). Injection has no human data.
FDA and compounding status [8] [9] [10] [15] [16]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous, intramuscular, oral, or topical) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).Topical: lawful cosmetic ingredient if no drug claims are made; non-injectable GHK-Cu is in 503A Category 1 (in FDA review). Injectable: nomination withdrawn, so it is in no 503A category, is not on the bulks list, was not reviewed by PCAC, and is not covered by HHS's October 2026 draft policy. Not FDA approved as a drug.
Access without a prescription [8] [10] [14] [15]None. Under HHS's draft policy it is available only as a compounded product on a patient-specific prescription when the policy's conditions are met. Research chemical products sold for human use are still unapproved drugs.Topical cosmetic products are sold over the counter. Injectable GHK-Cu has no lawful compounded path: its nomination was withdrawn, it is not on the 503A bulks list, and HHS's October 2026 draft policy does not cover it.
WADA status [11]Prohibited at all times under S0 (non-approved substances).Not named on the list. Topical cosmetic use is not a recognized concern, but injected GHK-Cu may fall under S0 as a non-approved substance, so status is unclear.
Typical cost [8] [10] [15]No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. No lawful compounded price for injectable GHK-Cu, which is not on the 503A bulks list.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

BPC-157 and GHK-Cu: grade, status, and cost
AttributeBPC-157GHK-Cu
ClassSynthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compoundNaturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine
What it isA 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.Copper binding peptide used in skin cosmetics; one small randomized topical trial found no objective benefit. Injectable form is unapproved and untested.
EvidenceEvidence: Animal-only evidenceEvidence: Human RCT evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: Nomination withdrawn
CompoundingBPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it can be sold without FDA premarket approval, as long as the product makes no drug claims. As a drug it is not FDA approved. For compounding, FDA treats it by route. GHK-Cu for non-injectable routes is in 503A Category 1 (under evaluation). Under FDA's interim policy, FDA does not intend to act against a 503A pharmacy or physician that compounds it for an identified patient on a prescription, if the ingredient comes from a registered manufacturer with a valid certificate of analysis and all other 503A conditions are met. GHK-Cu for injectable routes was in Category 2 and is now on FDA's list of withdrawn nominations. That list is outside any category and outside the interim policy, so as of the last verification date a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk. FDA has said it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. FDA has also warned that 'research use only' labels do not make a product lawful when it is intended for use in people.
WADAWADA: WADA prohibitedWADA: WADA status unclear
RoutesSubcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies)Topical cream or serum (cosmetic use, the only form with human data), Subcutaneous injection (as sold; no human data), Topical, intraperitoneal, and systemic (animal studies)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has BPC-157 been tested directly against GHK-Cu?

No published trial has compared BPC-157 and GHK-Cu directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do BPC-157 and GHK-Cu cost?

Typical cost of BPC-157 and GHK-Cu
DimensionBPC-157GHK-Cu
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailBPC-157 price by channelGHK-Cu price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the BPC-157 page and the GHK-Cu page.

Are BPC-157 and GHK-Cu combined?

BPC-157 and GHK-Cu are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.

  • GLOW: No federal basis to compound.
  • KLOW: No federal basis to compound.

Frequently asked questions

Which is better for skin, BPC-157 or GHK-Cu?

GHK-Cu. Small controlled cosmetic studies of topical GHK-Cu creams report tighter skin, better elasticity and density, and fewer fine lines, and those products are sold over the counter. The one small randomized trial, after laser resurfacing, found no difference in redness, wrinkles, or skin quality by blinded assessment. BPC-157 has no human skin data. [6] [7] [10] [13]

Which is better for tendon or joint injuries?

Neither has human evidence for tendon or joint injuries. BPC-157 has rodent tendon studies showing faster Achilles healing; GHK-Cu animal data focus on skin, hair follicle, and bone healing. Standard care remains physical therapy and load management. [1] [2] [5]

Is injectable GHK-Cu better studied than injectable BPC-157?

No. Neither has a controlled human trial of injection. BPC-157 has three small uncontrolled pilot reports from one clinic, and GHK-Cu's human data come only from topical cosmetic products, which tell you nothing about injected doses or safety. [6] [12]

Can I get either one legally?

Topical GHK-Cu is sold as a cosmetic ingredient in creams and serums as long as no drug claims are made. BPC-157 is not FDA approved or on the 503A bulks list, but it is one of six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy, which covers single-ingredient compounding on a patient-specific prescription (subcutaneous, intramuscular, oral, or topical) when sourcing, testing, and reporting conditions are met. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Injectable GHK-Cu is not covered: its nomination was withdrawn and it is not on the bulks list. The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Research chemical vials sold for human use are still unapproved drugs, and state law still applies. [8] [9] [10] [14] [15] [16]

Do both carry a cancer concern?

Both have a theoretical concern because they promote angiogenesis or cell proliferation in animal and cell models, though neither has been shown to promote tumors in humans. Reviews of GHK also report anti-cancer activity in vitro, so the question is unresolved. [3] [5]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
  2. [2]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
  3. [3]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
  4. [4]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
  5. [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
  6. [6]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
  7. [7]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
  8. [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  9. [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  10. [10]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). BPC-157 vs GHK-Cu: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-ghk-cu
HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-ghk-cu">BPC-157 vs GHK-Cu: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.